Free Trial

Prakhar Agrawal Analyst Performance

Analyst at Cantor Fitzgerald

Prakhar Agrawal is a stock analyst at Cantor Fitzgerald in the medical sector, covering 6 publicly traded companies. Over the past year, Prakhar Agrawal has issued 6 stock ratings, including and buy recommendations. While full access to Prakhar Agrawal's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Prakhar Agrawal's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
8 Last 4 Years
Buy Recommendations
87.50% 7 Buy Ratings
Companies Covered
6 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy87.5%7 ratings
Hold12.5%1 ratings
Sell0.0%0 ratings

Out of 8 total stock ratings issued by Prakhar Agrawal at Cantor Fitzgerald, the majority (87.5%) have been Buy recommendations, followed by 12.5% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
6 companies

Prakhar Agrawal, an analyst at Cantor Fitzgerald, currently covers 6 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
6 companies
100.0%

Prakhar Agrawal of Cantor Fitzgerald specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
3 companies
50.0%
MED - DRUGS
1 company
16.7%
PHARMACEUTICAL PREPARATIONS
1 company
16.7%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company
16.7%

Prakhar Agrawal's Ratings History at Cantor Fitzgerald

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Metsera Inc. stock logo
MTSR
Metsera
9/3/2025Reiterated Rating$36.15Overweight
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
8/15/2025Initiated Coverage$8.95Overweight
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
6/23/2025Reiterated Rating$21.98$65.00Overweight
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
5/6/2025Reiterated Rating$5.70Overweight
Metsera Inc. stock logo
MTSR
Metsera
2/25/2025Initiated Coverage$30.15Overweight
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
1/14/2025Reiterated Rating$9.45Overweight